

Ibrahim Akin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8126298/publications.pdf>

Version: 2024-02-01

101
papers

1,893
citations

279798

23
h-index

289244

40
g-index

103
all docs

103
docs citations

103
times ranked

2125
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Term Prognosis of Patients With Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2018, 72, 874-882.	2.8	224
2	Lipopolysaccharides induced inflammatory responses and electrophysiological dysfunctions in human-induced pluripotent stem cell derived cardiomyocytes. <i>Scientific Reports</i> , 2017, 7, 2935.	3.3	111
3	Modeling Short QT Syndrome Using Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	88
4	Cardiac arrest in takotsubo syndrome: results from the InterTAK Registry. <i>European Heart Journal</i> , 2019, 40, 2142-2151.	2.2	79
5	Outcomes Associated With Cardiogenic Shock in Takotsubo Syndrome. <i>Circulation</i> , 2019, 139, 413-415.	1.6	75
6	Prevalence of malignant arrhythmia and sudden cardiac death in takotsubo syndrome and its management. <i>Europace</i> , 2018, 20, 843-850.	1.7	61
7	Ion Channel Expression and Characterization in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Stem Cells International</i> , 2018, 2018, 1-14.	2.5	60
8	Assessment of the German and Italian Stress Cardiomyopathy Score for Risk Stratification for In-hospital Complications in Patients With Takotsubo Syndrome. <i>JAMA Cardiology</i> , 2019, 4, 892.	6.1	60
9	Estradiol protection against toxic effects of catecholamine on electrical properties in human-induced pluripotent stem cell derived cardiomyocytes. <i>International Journal of Cardiology</i> , 2018, 254, 195-202.	1.7	55
10	Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. <i>Europace</i> , 2017, 19, 1288-1292.	1.7	54
11	Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. <i>Diabetes Care</i> , 2018, 41, 1084-1088.	8.6	53
12	Electrical dysfunctions in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with an arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , 2018, 20, f46-f56.	1.7	50
13	Coexistence and outcome of coronary artery disease in Takotsubo syndrome. <i>European Heart Journal</i> , 2020, 41, 3255-3268.	2.2	49
14	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.	2.9	49
15	Ischemic biomarker heart-type fatty acid binding protein (hFABP) in acute heart failure - diagnostic and prognostic insights compared to NT-proBNP and troponin I. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 50.	1.7	44
16	Age-Related Variations in Takotsubo Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1869-1877.	2.8	42
17	Cardiovascular Comorbidities in Chronic Obstructive Pulmonary Disease (COPD)â€”Current Considerations for Clinical Practice. <i>Journal of Clinical Medicine</i> , 2019, 8, 69.	2.4	40
18	Takotsubo Syndrome and Embolic Events. <i>Heart Failure Clinics</i> , 2016, 12, 543-550.	2.1	36

#	ARTICLE	IF	CITATIONS
19	Prevalence, management, and outcome of adverse rhythm disorders in takotsubo syndrome: insights from the international multicenter GEIST registry. <i>Heart Failure Reviews</i> , 2020, 25, 505-511.	3.9	35
20	Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 279-287.	2.4	34
21	Impact of Sacubitril/Valsartan on the Long-Term Incidence of Ventricular Arrhythmias in Chronic Heart Failure Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 1582.	2.4	33
22	Indication and short-term clinical outcomes of high-risk percutaneous coronary intervention with microaxial Impella® pump: results from the German Impella® registry. <i>Clinical Research in Cardiology</i> , 2018, 107, 653-657.	3.3	30
23	Impact of aspirin on takotsubo syndrome: a propensity score-based analysis of the InterTAK Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 330-337.	7.1	24
24	Implantable cardioverter-defibrillator in Brugada syndrome: Long-term follow-up. <i>Clinical Cardiology</i> , 2019, 42, 958-965.	1.8	21
25	Clinical and echocardiographic analysis of patients suffering from recurrent takotsubo cardiomyopathy. <i>Journal of Geriatric Cardiology</i> , 2016, 13, 888-893.	0.2	21
26	Prediction of short- and long-term mortality in takotsubo syndrome: the InterTAK Prognostic Score. <i>European Journal of Heart Failure</i> , 2019, 21, 1469-1472.	7.1	20
27	Long-term follow-up of implantable cardioverter-defibrillators in Short QT syndrome. <i>Clinical Research in Cardiology</i> , 2019, 108, 1140-1146.	3.3	20
28	Incidence, determinants and prognostic relevance of dyspnea at admission in patients with Takotsubo syndrome: results from the international multicenter GEIST registry. <i>Scientific Reports</i> , 2020, 10, 13603.	3.3	20
29	Left atrial appendage closure in patients with chronic kidney disease: results from the German multicentre LAARGE registry. <i>Clinical Research in Cardiology</i> , 2021, 110, 12-20.	3.3	20
30	Impact of Antiarrhythmic Drugs on the Outcome of Short QT Syndrome. <i>Frontiers in Pharmacology</i> , 2019, 10, 771.	3.5	18
31	Predicting Pulmonary Function Testing from Quantified Computed Tomography Using Machine Learning Algorithms in Patients with COPD. <i>Diagnostics</i> , 2019, 9, 33.	2.6	17
32	Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction. <i>Clinical Cardiology</i> , 2018, 41, 518-524.	1.8	15
33	Impact and management of left ventricular function on the prognosis of Takotsubo syndrome. <i>European Journal of Clinical Investigation</i> , 2017, 47, 477-485.	3.4	14
34	Arrhythmic events in Brugada syndrome patients induced by fever. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12723.	1.1	14
35	TRPV1 activation and internalization is part of the LPS-induced inflammation in human iPSC-derived cardiomyocytes. <i>Scientific Reports</i> , 2021, 11, 14689.	3.3	13
36	Takotsubo syndrome and cardiac implantable electronic device therapy. <i>Scientific Reports</i> , 2019, 9, 16559.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Sex-differences in short QT syndrome: A systematic literature review and pooled analysis. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1335-1338.	1.8	12
38	Differences in Short QT Syndrome Subtypes: A Systematic Literature Review and Pooled Analysis. <i>Frontiers in Genetics</i> , 2019, 10, 1312.	2.3	12
39	Single-dose of adreuzumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 247-254.	10.7	12
40	Percutaneous Closure of Left Atrial Appendage affects Mid-Term Release of MR-proANP. <i>Scientific Reports</i> , 2017, 7, 9028.	3.3	11
41	The evolution of activated protein C plasma levels in septic shock and its association with mortality: A prospective observational study. <i>Journal of Critical Care</i> , 2018, 47, 41-48.	2.2	11
42	Deciphering the pathogenic role of a variant with uncertain significance for short QT and Brugada syndromes using gene-edited human-induced pluripotent stem cell-derived cardiomyocytes and preclinical drug screening. <i>Clinical and Translational Medicine</i> , 2021, 11, e646.	4.0	11
43	Ionic Mechanisms of Disopyramide Prolonging Action Potential Duration in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. <i>Frontiers in Pharmacology</i> , 2020, 11, 554422.	3.5	10
44	Different genotypes of Brugada syndrome may present different clinical phenotypes: electrophysiology from bench to bedside. <i>European Heart Journal</i> , 2021, 42, 1270-1272.	2.2	10
45	Incidence and Prognostic Relevance of Cardiopulmonary Failure in Takotsubo Cardiomyopathy. <i>Scientific Reports</i> , 2017, 7, 14673.	3.3	9
46	Small Airway Disease in Pulmonary Hypertension—Additional Diagnostic Value of Multiple Breath Washout and Impulse Oscillometry. <i>Journal of Clinical Medicine</i> , 2018, 7, 532.	2.4	9
47	Association of Culprit Lesion Location With Outcomes of Culprit-Lesion-Only vs Immediate Multivessel Percutaneous Coronary Intervention in Cardiogenic Shock. <i>JAMA Cardiology</i> , 2020, 5, 1329.	6.1	9
48	Prediction of aortic dissection. <i>Heart</i> , 2020, 106, 870-871.	2.9	9
49	Short-term and long-term incidence of stroke in Takotsubo syndrome. <i>ESC Heart Failure</i> , 2018, 5, 1191-1194.	3.1	8
50	Prognostic impact of acute pulmonary triggers in patients with takotsubo syndrome: new insights from the International Takotsubo Registry. <i>ESC Heart Failure</i> , 2021, 8, 1924-1932.	3.1	8
51	Ethnic comparison in takotsubo syndrome: novel insights from the International Takotsubo Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 186-196.	3.3	8
52	Interventional Left Atrial Appendage Closure Affects the Metabolism of Acylcarnitines. <i>International Journal of Molecular Sciences</i> , 2018, 19, 500.	4.1	7
53	Impeding Sudden Cardiac Death Despite Subcutaneous Implantable Defibrillator Due to Fatal Crosstalk. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 613-614.	1.7	6
54	Biomarker evaluation as a potential cause of gender differences in obesity paradox among patients with STEMI. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 88-94.	0.8	6

#	ARTICLE	IF	CITATIONS
55	The link between atrial fibrillation and hereditary channelopathies. <i>Europace</i> , 2018, 20, 1872-1872.	1.7	6
56	Serum of patients with acute myocardial infarction prevents inflammation in iPSC-cardiomyocytes. <i>Scientific Reports</i> , 2019, 9, 5651.	3.3	6
57	Left atrial appendage closure in patients with a reduced left ventricular ejection fraction: results from the multicenter German LAARGE registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 1333-1341.	3.3	6
58	Long-Term Follow-Up of Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. <i>Journal of Clinical Medicine</i> , 2020, 9, 903.	2.4	6
59	Pooled Analysis of Complications with Transvenous ICD Compared to Subcutaneous ICD in Patients with Catecholaminergic Polymorphic Ventricular Arrhythmia. <i>Journal of Personalized Medicine</i> , 2022, 12, 536.	2.5	6
60	Bedside implantation of a new temporary vena cava inferior filter - Safety and efficacy results of the European ANGEL-Registry. <i>Journal of Critical Care</i> , 2018, 44, 39-44.	2.2	5
61	Protective effect of acquired long QT syndrome in Takotsubo syndrome. <i>Internal Medicine Journal</i> , 2019, 49, 770-776.	0.8	5
62	Characterization of circulating thrombin in patients with septic shock: a prospective observational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 90-97.	2.1	5
63	Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. <i>Frontiers in Pharmacology</i> , 2021, 12, 675003.	3.5	5
64	Impact of baseline left ventricular ejection fraction on long-term outcomes in cardiac contractility modulation therapy. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 639-648.	1.2	5
65	Catecholamine in takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 233, 97.	1.7	4
66	Clinical Outcomes According to ECG Presentations in Infarct-Related Cardiogenic Shock in the Culprit Lesion Only PCI vs Multivessel PCI in Cardiogenic Shock Trial. <i>Chest</i> , 2021, 159, 1415-1425.	0.8	4
67	Recent Developments in Drug-Eluting Coronary Stents. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2014, 14, 220-224.	0.7	4
68	Comparison of the Outcome of Patients Protected by the Wearable Cardioverter Defibrillator (WCD) for ≥ 90 Wear Days versus <math>< 90</math> Wear Days. <i>In Vivo</i> , 2020, 34, 3601-3610.	1.3	4
69	Atrial fibrillation as a risk factor for worse outcome in acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 246, 53.	1.7	3
70	Endothelial dysfunction in takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 234, 101.	1.7	3
71	<p>Impact of ST-segment elevation on the outcome of Takotsubo syndrome</p>. <i>Therapeutics and Clinical Risk Management</i> , 2019, Volume 15, 251-258.	2.0	3
72	Impact of T-wave inversion on the outcome of Takotsubo syndrome as compared to acute coronary syndrome. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13078.	3.4	3

#	ARTICLE	IF	CITATIONS
73	Clinical Profile and Long-Term Follow-Up of Children with Brugada Syndrome. <i>Pediatric Cardiology</i> , 2020, 41, 290-296.	1.3	3
74	Prognostic impact of potassium levels in patients with ventricular tachyarrhythmias. <i>Clinical Research in Cardiology</i> , 2020, 109, 1292-1306.	3.3	3
75	Letter by El-Battrawy et al Regarding Article, "The Brugada Syndrome Susceptibility Gene HEY2 Modulates Cardiac Transmural Ion Channel Patterning and Electrical Heterogeneity". <i>Circulation Research</i> , 2017, 121, e20.	4.5	2
76	Response to Comment on Stiermaier et al. Prevalence and Prognostic Impact of Diabetes in Takotsubo Syndrome: Insights From the International, Multicenter GEIST Registry. <i>Diabetes Care</i> 2018;41:1084-1088. <i>Diabetes Care</i> , 2018, 41, e122-e122.	8.6	2
77	The current evidence of Takotsubo syndrome. <i>Future Cardiology</i> , 2021, 17, 1293-1295.	1.2	2
78	Abnormal Cardiac Repolarization in Thyroid Diseases: Results of an Observational Study. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 738517.	2.4	2
79	Antiarrhythmic Effects of Vernakalant in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Short QT Syndrome Type 1. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 112.	1.6	2
80	Reply to: Diabetes mellitus and Takotsubo syndrome: Dissecting the paradox. <i>International Journal of Cardiology</i> , 2017, 229, 135.	1.7	1
81	Letter by El-Battrawy et al Regarding Article, "Takotsubo-Like Myocardial Dysfunction in Ischemic Stroke: A Hospital-Based Registry and Systematic Literature Review". <i>Stroke</i> , 2017, 48, e72.	2.0	1
82	Feasibility of drugs in Brugada syndrome. <i>Europace</i> , 2018, 20, f137-f137.	1.7	1
83	Psychiatric Disease Among Patients With Takotsubo Syndrome. <i>Psychosomatics</i> , 2018, 59, 101-102.	2.5	1
84	Atrial fibrillation impacts the outcome in Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2018, 251, 57.	1.7	1
85	The pathophysiology of arrhythmias in arrhythmogenic right ventricular cardiomyopathy. <i>Europace</i> , 2018, 20, f138-f138.	1.7	1
86	Cardiac voltage-sodium channel mutations association with primary electrical diseases. <i>Europace</i> , 2018, 20, 1707-1707.	1.7	1
87	Predictors of thromboembolic events in Takotsubo syndrome. <i>European Journal of Heart Failure</i> , 2019, 21, 1482-1482.	7.1	1
88	"Mature" resting membrane potentials in hiPSC-CMs: fact or artefact? Authors' reply. <i>Europace</i> , 2019, 21, 1928-1929.	1.7	1
89	Comparison between treatment of "established" versus complex "off-label" coronary lesions with AbsorbÂ® bioresorbable scaffold implantation: results from the GABI-RÂ® registry. <i>Clinical Research in Cardiology</i> , 2020, 109, 374-384.	3.3	1
90	Ticagrelor after Acute Coronary Syndrome: One For All or Part of Personalized Medicine?. <i>Lancet Regional Health - Europe</i> , The, 2022, 14, 100309.	5.6	1

#	ARTICLE	IF	CITATIONS
91	A Case Series of Concomitant Cardiac Electrical Disease among Takotsubo Syndrome Patients and Literature Review. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 79.	1.6	1
92	Impact of stress on Takotsubo syndrome. <i>International Journal of Cardiology</i> , 2017, 242, 33.	1.7	0
93	Dissecting the diagnosis of biventricular myocarditis. <i>International Journal of Cardiology</i> , 2017, 242, 43.	1.7	0
94	Sodium channel blockers in Brugada syndrome. <i>Europace</i> , 2018, 20, f139-f139.	1.7	0
95	Letter by El-Battrawy et al Regarding Article, "The Effects of Public Access Defibrillation on Survival After Out-of-Hospital Cardiac Arrest: A Systematic Review of Observational Studies" <i>Circulation</i> , 2018, 137, 1646-1647.	1.6	0
96	Letter by El-Battrawy et al Regarding Article, "Female Sex Is a Risk Modifier Rather Than a Risk Factor for Stroke in Atrial Fibrillation: Should We Use a CHA ₂ DS ₂ -VASc-VA Score Rather Than CHA ₂ DS ₂ -VASc?" <i>Circulation</i> , 2018, 138, 441-442.	1.6	0
97	Sleep apnea as an attributable risk for atrial fibrillation. <i>International Journal of Cardiology</i> , 2018, 264, 103.	1.7	0
98	Letter by El-Battrawy et al Regarding Article, "Sex Differences and Similarities in Atrial Fibrillation Epidemiology, Risk Factors, and Mortality in Community Cohorts: Results From the BiomarcARE Consortium (Biomarker for Cardiovascular Risk Assessment in Europe)" <i>Circulation</i> , 2018, 137, 2083-2084.	1.6	0
99	Delta CHA ₂ DS ₂ -VASc score as a predictor of stroke. <i>Europace</i> , 2019, 21, 179-179.	1.7	0
100	Noninvasive measurement of hemodynamic response to postural stress using inert gas rebreathing. <i>Biomedical Reports</i> , 2019, 11, 98-102.	2.0	0
101	Letter by El-Battrawy et al Regarding Article, "Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis" <i>Circulation</i> , 2019, 139, 1344-1345.	1.6	0